iX Biopharma Statistics

Total Valuation

iX Biopharma has a market cap or net worth of SGD 17.67 million. The enterprise value is 20.52 million.

Market Cap	17.67M
Enterprise Value	20.52M

Important Dates

The last earnings date was Tuesday, February 4, 2025.

Earnings Date	Feb 4, 2025
Ex-Dividend Date	n/a

Share Statistics

iX Biopharma has 883.34 million shares outstanding. The number of shares has increased by 7.03% in one year.

Current Share Class	n/a
Shares Outstanding	883.34M
Shares Change (YoY)	+7.03%
Shares Change (QoQ)	+13.51%
Owned by Insiders (%)	44.54%
Owned by Institutions (%)	0.10%
Float	457.91M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.34
PB Ratio	5.03
P/TBV Ratio	5.45
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.11
EV / Sales	2.93
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.56

Financial Position

The company has a current ratio of 0.78, with a Debt / Equity ratio of 1.40.

Current Ratio	0.78
Quick Ratio	0.58
Debt / Equity	1.40
Debt / EBITDA	n/a
Debt / FCF	-0.85
Interest Coverage	-25.93

Financial Efficiency

Return on equity (ROE) is -173.93% and return on invested capital (ROIC) is -43.11%.

Return on Equity (ROE)	-173.93%
Return on Assets (ROA)	-30.36%
Return on Invested Capital (ROIC)	-43.11%
Return on Capital Employed (ROCE)	-128.44%
Revenue Per Employee	166,667
Profits Per Employee	-231,310
Employee Count	42
Asset Turnover	0.45
Inventory Turnover	5.65

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -53.49% in the last 52 weeks. The beta is 0.76, so iX Biopharma's price volatility has been lower than the market average.

Beta (5Y)	0.76
52-Week Price Change	-53.49%
50-Day Moving Average	0.02
200-Day Moving Average	0.03
Relative Strength Index (RSI)	36.45
Average Volume (20 Days)	349,635

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, iX Biopharma had revenue of SGD 7.00 million and -9.72 million in losses. Loss per share was -0.01.

Revenue	7.00M
Gross Profit	1.29M
Operating Income	-7.62M
Pretax Income	-10.29M
Net Income	-9.72M
EBITDA	-7.21M
EBIT	-7.62M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 2.07 million in cash and 4.92 million in debt, giving a net cash position of -2.86 million or -0.00 per share.

Cash & Cash Equivalents	2.07M
Total Debt	4.92M
Net Cash	-2.86M
Net Cash Per Share	-0.00
Equity (Book Value)	3.51M
Book Value Per Share	0.00
Working Capital	-1.57M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -5.57 million and capital expenditures -204,000, giving a free cash flow of -5.77 million.

Operating Cash Flow	-5.57M
Capital Expenditures	-204,000
Free Cash Flow	-5.77M
FCF Per Share	-0.01

Full Cash Flow Statement

Margins

Gross margin is 18.37%, with operating and profit margins of -108.91% and -138.79%.

Gross Margin	18.37%
Operating Margin	-108.91%
Pretax Margin	-146.96%
Profit Margin	-138.79%
EBITDA Margin	-102.99%
EBIT Margin	-108.91%
FCF Margin	n/a

Dividends & Yields

iX Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.03%
Shareholder Yield	-7.03%
Earnings Yield	-54.99%
FCF Yield	-32.66%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

iX Biopharma has an Altman Z-Score of -10.88. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.88
Piotroski F-Score	n/a